Pinter M M, Helscher R J
Neurological Hospital Rosenhügel, Vienna, Austria.
J Neural Transm Park Dis Dement Sect. 1993;5(2):135-46. doi: 10.1007/BF02251204.
Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored. Paranoid ideas disappeared in all seven patients after a maximum of four days administration of 25-125 mg/day. No deterioration of parkinsonian symptoms, quantified according to UPDRS was seen. Given the protection of clozapine, we could increase the L-dopa dose in two cases, thereby improving the patients' motor function. Blood count showed no abnormalities in any of the patients during an average observation period of seventeen months. Our results support the assumption that clozapine has a potent antipsychotic effect in the treatment of psychotic decompensation in advanced Parkinson's disease in carefully selected patients. We saw no negative influence of the neuroleptic on extrapyramidal symptoms.
7例特发性帕金森病患者,年龄62至76岁,病程平均约11年,患有不同程度的严重幻觉症和偏执妄想,常规治疗策略(给予苯二氮䓬类药物和轻度抗精神病药)无抗精神病作用,接受了氯氮平(一种非经典高效抗精神病药)治疗,同时严格监测血常规。7例患者在每日服用25 - 125mg最多4天后,偏执观念均消失。根据统一帕金森病评定量表(UPDRS)量化评估,未见帕金森症状恶化。鉴于氯氮平的保护作用,我们在2例患者中增加了左旋多巴剂量,从而改善了患者的运动功能。在平均17个月的观察期内,所有患者的血常规均未见异常。我们的结果支持以下假设:在精心挑选的患者中,氯氮平在治疗晚期帕金森病的精神失代偿方面具有强大的抗精神病作用。我们未观察到该抗精神病药对锥体外系症状有负面影响。